The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 29th 2025
A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.
Health Care Professionals Bring Drug Shortage Concerns to Capitol Hill
April 26th 2019Last week, National Association of EMS Physicians members joined with other health care professionals on Capitol Hil to bring attention to the issue of drug shortages, as emergency medical facilities across the country are forced to severely restrict use of certain IV fluids, anti-nausea medications, airway management medications, and other essential emergency medications (EEMs).
Read More
Teva Recalls 35 Lots of Bulk Losartan Potassium Tablets
April 26th 2019According to Teva, this recall was initiated by detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in 6 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit.
Read More
ASHP Joins National Academy of Medicine Action Collaborative on Countering the US Opioid Epidemic
April 25th 2019The mission of the Action Collaborative is to convene and catalyze public, private, and nonprofit stakeholders to develop, curate, and disseminate multisector solutions designed to reduce opioid misuse and improve outcomes for individuals, families, and communities affected by the opioid crisis.
Read More
FDA Approves New Therapy for Moderate to Severe Plaque Psoriasis
April 24th 2019In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).
Read More
New Federal Primary Care Payment Models: Another Step Toward Value Based Care
April 22nd 2019The Center for Medicare and Medicaid Innovation (CMMI) will be inviting primary care practices to participate in 5 new alternative payment models that will allow primary care practices to provide new types of services to their patients that are not supported by current Medicare payments.
Read More
FDA Approves Pembrolizumab Combo Therapy for Advanced Renal Cell Carcinoma
April 22nd 2019Pembrolizumab (Keytruda, Merck) has received FDA approval as a first-line treatment in combination with axitinib (Inlyta) for patients with advanced renal cell carcinoma (RCC), making it the first indication for pembrolizumab in this patient population.
Read More
Study Shows Precancerous Cervical Lesions Have Declined
April 22nd 2019Precancerous cervical lesions, known as high-grade cervical lesions (CIN2+) can develop a few years after infection and have been used to monitor human papillomavirus (HPV) vaccine impact since cancers can take decades to develop.
Read More
Hormone Therapy Combination Now Available for Treating Hot Flashes in Menopausal Women
April 18th 2019The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.
Read More
Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial
April 17th 2019The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
Read More
New Treatment for Osteoporosis In Postmenopausal Women is Available
April 16th 2019Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Read More